274 related articles for article (PubMed ID: 23918169)
1. Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database.
Cho SK; Sung YK; Choi CB; Kwon JM; Lee EK; Bae SC
Rheumatol Int; 2013 Dec; 33(12):2985-92. PubMed ID: 23918169
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data.
Chung CP; Rohan P; Krishnaswami S; McPheeters ML
Vaccine; 2013 Dec; 31 Suppl 10():K41-61. PubMed ID: 24331074
[TBL] [Abstract][Full Text] [Related]
3. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan.
Katada H; Yukawa N; Urushihara H; Tanaka S; Mimori T; Kawakami K
Clin Rheumatol; 2015 May; 34(5):949-56. PubMed ID: 24420724
[TBL] [Abstract][Full Text] [Related]
4. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
5. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
[TBL] [Abstract][Full Text] [Related]
6. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
7. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
[TBL] [Abstract][Full Text] [Related]
8. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
9. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization.
Won S; Cho SK; Kim D; Han M; Lee J; Jang EJ; Sung YK; Bae SC
Rheumatol Int; 2018 Apr; 38(4):649-656. PubMed ID: 29302803
[TBL] [Abstract][Full Text] [Related]
10. Validation of rheumatoid arthritis diagnoses in health care utilization data.
Kim SY; Servi A; Polinski JM; Mogun H; Weinblatt ME; Katz JN; Solomon DH
Arthritis Res Ther; 2011 Feb; 13(1):R32. PubMed ID: 21345216
[TBL] [Abstract][Full Text] [Related]
11. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
[TBL] [Abstract][Full Text] [Related]
12. National pharmacological treatment trends for ankylosing spondylitis in South Korea: A national health insurance database study.
Park JS; Hong JY; Kim HK; Koo B; Kim SH; Kwon YC
PLoS One; 2020; 15(10):e0240155. PubMed ID: 33021982
[TBL] [Abstract][Full Text] [Related]
13. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
14. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
Popp RA; Rascati K; Davis M; Patel U
Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide for rheumatoid arthritis.
Drug Ther Bull; 2000 Jul; 38(7):52-4. PubMed ID: 11027115
[TBL] [Abstract][Full Text] [Related]
16. Utilization patterns of disease-modifying antirheumatic drugs in elderly rheumatoid arthritis patients.
Jin XM; Lee J; Choi NK; Seong JM; Shin JY; Kim YJ; Kim MS; Yang BR; Park BJ
J Korean Med Sci; 2014 Feb; 29(2):210-6. PubMed ID: 24550647
[TBL] [Abstract][Full Text] [Related]
17. Trends in total elbow arthroplasty in patients with rheumatoid arthritis receiving disease-modifying antirheumatic drug therapy based on payer status.
Ahiarakwe U; Zachary Pearson ; Ochuba A; Kim W; Pressman Z; Haft M; Srikumaran U; Best MJ
J Shoulder Elbow Surg; 2023 Oct; 32(10):2132-2139. PubMed ID: 37348781
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Rheumatoid Arthritis and Drug Dispensing Patterns Among Medicaid and Medicaid-Medicare Dually Eligible Beneficiaries in Puerto Rico.
Hernández-Muñoz JJ; Wei W; Sierra-Zorita R
Arthritis Care Res (Hoboken); 2021 Feb; 73(2):199-206. PubMed ID: 32475025
[TBL] [Abstract][Full Text] [Related]
19. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.
Scott DL; Strand V
Rheumatology (Oxford); 2002 Aug; 41(8):899-909. PubMed ID: 12154207
[TBL] [Abstract][Full Text] [Related]
20. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
Cannon GW; Holden WL; Juhaeri J; Dai W; Scarazzini L; Stang P
J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
